Transaction DateRecipientSharesTypePriceValue
19th January 2021Vincent O'Neill12,665Open or private sale$49.27$624,004.55
19th January 2021Vincent O'Neill1,377Open or private sale$52.45$72,223.65
19th January 2021Vincent O'Neill2,700Open or private sale$50.38$136,026.00
19th January 2021Vincent O'Neill1,500Open or private sale$51.45$77,175.00
19th January 2021Vincent O'Neill25,000Exercise of derivative$0.41$10,250.00
19th January 2021Vincent O'Neill6,758Open or private sale$48.43$327,289.94
28th December 2020Vincent O'Neill3,951Open or private sale$52.68$208,138.68
28th December 2020Vincent O'Neill13,969Open or private sale$50.77$709,206.13
28th December 2020Vincent O'Neill1,353Open or private sale$53.54$72,439.62
28th December 2020Vincent O'Neill25,000Exercise of derivative$0.41$10,250.00
Bio Xcel Therapeutics
Bio Xcel Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Ticker: BTAI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1720893
Employees: 24
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags